Symbols / AIM $0.68 -3.53%
AIM Chart
About
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.85M |
| Enterprise Value | 1.86M | Income | -15.75M | Sales | 112.00K |
| Book/sh | -2.20 | Cash/sh | 0.84 | Dividend Yield | — |
| Payout | 0.00% | Employees | 21 | IPO | — |
| P/E | — | Forward P/E | -0.16 | PEG | — |
| P/S | 25.45 | P/B | -0.31 | P/C | — |
| EV/EBITDA | -0.13 | EV/Sales | 16.59 | Quick Ratio | 0.60 |
| Current Ratio | 0.64 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -18.16 | EPS next Y | -4.33 | EPS Growth | — |
| Revenue Growth | -25.70% | Earnings | 2025-11-17 16:00 | ROA | -95.42% |
| ROE | — | ROIC | — | Gross Margin | 15.18% |
| Oper. Margin | -94.12% | Profit Margin | 0.00% | Shs Outstand | 4.22M |
| Shs Float | 2.78M | Short Float | 2.29% | Short Ratio | 0.03 |
| Short Interest | — | 52W High | 34.92 | 52W Low | 0.61 |
| Beta | 1.25 | Avg Volume | 1.49M | Volume | 111.60K |
| Target Price | $13.99 | Recom | None | Prev Close | $0.70 |
| Price | $0.68 | Change | -3.53% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.99
Mean price target
2. Current target
$0.68
Latest analyst target
3. DCF / Fair value
$-60.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.68
Low
$5.99
High
$21.98
Mean
$13.99
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-08 | main | Ascendiant Capital | Buy → Buy | $22 |
| 2025-10-03 | main | Ascendiant Capital | Buy → Buy | $24 |
| 2024-12-10 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2024-10-22 | main | Maxim Group | Buy → Buy | $1 |
| 2024-09-03 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2019-10-10 | up | Maxim Group | Hold → Buy | — |
News
RSS: Latest AIM news- Cancer-drug developer AIM ImmunoTech draws $1.8M in $1,000 rights sale - Stock Titan Sat, 07 Mar 2026 00
- Huddled Group shareholders back share issue as AIM listing enlarged - TipRanks Wed, 11 Mar 2026 14
- David Docherty Acquires 21,804 Shares of Octopus AIM VCT (LON:OOA) Stock - MarketBeat Mon, 09 Mar 2026 16
- London Stock Exchange Sets Out Reforms to AIM Rules - Skadden, Arps, Slate, Meagher & Flom LLP Mon, 08 Dec 2025 08
- Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance hu, 08 Jan 2026 08
- UK Capital Markets: Shaping the future of AIM – what’s changing now and what’s on the horizon? - www.hoganlovells.com Wed, 26 Nov 2025 08
- Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) Oscillate Update, Warrant Exercise & TVR - Share Talk Mon, 09 Mar 2026 11
- Investors get $1,000 AIM unit with 2,000 warrants — but clock is ticking - Stock Titan Fri, 27 Feb 2026 08
- Zenova says reverse takeover progressing as AIM share suspension continues - TipRanks Wed, 11 Mar 2026 07
- Aimia (TSE:AIM) Shares Cross Above Two Hundred Day Moving Average - Should You Sell? - MarketBeat Fri, 06 Mar 2026 09
- Experimental drug combo shows survival promise in pancreatic cancer trial - Stock Titan hu, 05 Feb 2026 08
- Naked Wines chair-linked fund lifts stake with fresh AIM share purchase - TipRanks ue, 10 Mar 2026 07
- Aimia (TSE:AIM) Stock Price Passes Above Two Hundred Day Moving Average - Here's What Happened - MarketBeat hu, 26 Feb 2026 08
- AIM cancer-drug investors get new March 3 deadline, use-it-or-lose-it rights - Stock Titan Wed, 25 Feb 2026 08
- AIM ImmunoTech Completes Series G Preferred Rights Offering - TipRanks Fri, 06 Mar 2026 22
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2800 | 3444 | — | Stock Award(Grant) at price 1.23 per share. | CHEMEROW DAVID I | Director | — | 2026-02-05 00:00:00 | I |
| 1 | 107 | 824 | — | Purchase at price 7.70 per share. | EQUELS THOMAS K | Chief Executive Officer | — | 2025-06-13 00:00:00 | D |
| 2 | 103 | 9 | — | Purchase at price 0.08 per share. | EQUELS THOMAS K | Chief Executive Officer | — | 2025-06-12 00:00:00 | D |
| 3 | 1968504 | 50000 | — | Purchase at price 0.03 per share. | EQUELS THOMAS K | Chief Executive Officer | — | 2025-04-11 00:00:00 | D |
| 4 | 1968504 | 50000 | — | Purchase at price 0.03 per share. | KELLNER TED D | Director | — | 2025-04-11 00:00:00 | D |
| 5 | 196851 | 5000 | — | Purchase at price 0.03 per share. | MITCHELL WILLIAM M | Director | — | 2025-04-11 00:00:00 | D |
| 6 | 1968504 | 50000 | — | Purchase at price 0.03 per share. | KELLNER TED D | Director | — | 2025-04-11 00:00:00 | D |
| 7 | 41000 | 2583 | — | Purchase at price 0.06 per share. | EQUELS THOMAS K | Chief Executive Officer | — | 2025-04-04 00:00:00 | D |
| 8 | 500 | 44 | — | Purchase at price 0.09 per share. | RODINO PETER W III | Chief Operating Officer | — | 2025-04-04 00:00:00 | D |
| 9 | 44899 | 5208 | — | Stock Award(Grant) at price 0.12 per share. | CHEMEROW DAVID I | Director | — | 2025-03-14 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.94M | -28.94M | -18.03M | -13.96M |
| TotalUnusualItems | -551.00K | 218.00K | -1.64M | -4.32M |
| TotalUnusualItemsExcludingGoodwill | -551.00K | 218.00K | -1.64M | -4.32M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.32M | -28.96M | -19.45M | -19.13M |
| ReconciledDepreciation | 246.00K | 238.00K | 256.00K | 775.00K |
| ReconciledCostOfRevenue | 31.00K | 42.00K | 0.00 | 850.00K |
| EBITDA | -16.49M | -28.72M | -19.67M | -18.29M |
| EBIT | -16.73M | -28.96M | -19.92M | -19.06M |
| NetInterestIncome | 4.61M | 1.07M | 629.00K | -67.00K |
| InterestExpense | 585.00K | 0.00 | 0.00 | 67.00K |
| InterestIncome | 5.19M | 1.07M | 629.00K | 0.00 |
| NormalizedIncome | -16.77M | -29.18M | -17.80M | -14.81M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.32M | -28.96M | -19.45M | -19.13M |
| TotalExpenses | 19.94M | 32.12M | 20.06M | 17.19M |
| TotalOperatingIncomeAsReported | -19.77M | -31.92M | -19.92M | -18.84M |
| DilutedAverageShares | 560.73K | 486.34K | 480.95K | 473.87K |
| BasicAverageShares | 560.73K | 486.34K | 480.95K | 473.87K |
| DilutedEPS | -30.97 | -59.94 | -39.96 | -39.96 |
| BasicEPS | -30.97 | -59.94 | -39.96 | -39.96 |
| DilutedNIAvailtoComStockholders | -17.32M | -28.96M | -19.45M | -19.13M |
| NetIncomeCommonStockholders | -17.32M | -28.96M | -19.45M | -19.13M |
| NetIncome | -17.32M | -28.96M | -19.45M | -19.13M |
| NetIncomeIncludingNoncontrollingInterests | -17.32M | -28.96M | -19.45M | -19.13M |
| NetIncomeContinuousOperations | -17.32M | -28.96M | -19.45M | -19.13M |
| PretaxIncome | -17.32M | -28.96M | -19.45M | -19.13M |
| OtherIncomeExpense | -2.15M | 1.89M | -151.00K | -2.00M |
| OtherNonOperatingIncomeExpenses | -1.60M | 1.67M | 1.49M | 2.32M |
| SpecialIncomeCharges | 0.00 | 18.00K | 3.00K | -4.26M |
| GainOnSaleOfPPE | 0.00 | 18.00K | 3.00K | 216.00K |
| OtherSpecialCharges | 2.70M | |||
| WriteOff | 0.00 | 1.78M | ||
| ImpairmentOfCapitalAssets | 1.78M | |||
| GainOnSaleOfSecurity | -551.00K | 200.00K | -1.64M | -56.00K |
| NetNonOperatingInterestIncomeExpense | 4.61M | 1.07M | 629.00K | -67.00K |
| InterestExpenseNonOperating | 585.00K | 0.00 | 0.00 | 67.00K |
| InterestIncomeNonOperating | 5.19M | 1.07M | 629.00K | 0.00 |
| OperatingIncome | -19.77M | -31.92M | -19.92M | -17.06M |
| OperatingExpense | 19.91M | 32.08M | 20.06M | 16.34M |
| ResearchAndDevelopment | 6.20M | 10.94M | 6.99M | 7.67M |
| SellingGeneralAndAdministration | 13.71M | 21.14M | 13.07M | 8.67M |
| GeneralAndAdministrativeExpense | 13.71M | 21.14M | 13.07M | 8.67M |
| OtherGandA | 13.71M | 21.14M | 13.07M | 8.67M |
| GrossProfit | 139.00K | 160.00K | 141.00K | -715.00K |
| CostOfRevenue | 31.00K | 42.00K | 0.00 | 850.00K |
| TotalRevenue | 170.00K | 202.00K | 141.00K | 135.00K |
| OperatingRevenue | 170.00K | 202.00K | 141.00K | 135.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 655.92K | 491.51K | 481.32K | 480.43K |
| ShareIssued | 655.92K | 491.51K | 481.32K | 480.43K |
| NetDebt | 606.00K | |||
| TotalDebt | 2.94M | 718.00K | 837.00K | 149.00K |
| TangibleBookValue | -3.92M | 7.23M | 35.83M | 54.19M |
| InvestedCapital | 985.00K | 9.54M | 37.77M | 56.16M |
| WorkingCapital | -5.36M | 5.90M | 34.96M | 49.54M |
| NetTangibleAssets | -3.92M | 7.92M | 36.53M | 54.91M |
| CapitalLeaseObligations | 634.00K | 718.00K | 837.00K | 149.00K |
| CommonStockEquity | -1.32M | 9.54M | 37.77M | 56.16M |
| PreferredStockEquity | 689.00K | 696.00K | 715.00K | |
| TotalCapitalization | -1.32M | 10.23M | 38.47M | 56.88M |
| TotalEquityGrossMinorityInterest | -1.32M | 10.23M | 38.47M | 56.88M |
| StockholdersEquity | -1.32M | 10.23M | 38.47M | 56.88M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | |||
| RetainedEarnings | -426.83M | -409.51M | -380.55M | -361.10M |
| AdditionalPaidInCapital | 425.44M | 419.00M | 418.27M | 417.22M |
| CapitalStock | 66.00K | 738.00K | 744.00K | 763.00K |
| CommonStock | 66.00K | 49.00K | 48.00K | 48.00K |
| PreferredStock | 0.00 | 689.00K | 696.00K | 715.00K |
| TotalLiabilitiesNetMinorityInterest | 9.93M | 9.15M | 2.02M | 820.00K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 395.00K | 495.00K | 659.00K | 147.00K |
| DerivativeProductLiabilities | 0.00 | 35.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 395.00K | 495.00K | 659.00K | 112.00K |
| LongTermCapitalLeaseObligation | 395.00K | 495.00K | 659.00K | 112.00K |
| CurrentLiabilities | 9.54M | 8.65M | 1.36M | 673.00K |
| CurrentDebtAndCapitalLeaseObligation | 2.55M | 223.00K | 178.00K | 37.00K |
| CurrentCapitalLeaseObligation | 239.00K | 223.00K | 178.00K | 37.00K |
| CurrentDebt | 2.31M | |||
| OtherCurrentBorrowings | 2.31M | |||
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.00K | 414.00K | 1.00K | 1.00K |
| PayablesAndAccruedExpenses | 6.99M | 8.02M | 1.18M | 635.00K |
| CurrentAccruedExpenses | 605.00K | 1.57M | 805.00K | 437.00K |
| InterestPayable | 11.00K | 0.00 | ||
| Payables | 6.38M | 6.44M | 377.00K | 198.00K |
| AccountsPayable | 6.38M | 6.44M | 377.00K | 198.00K |
| TotalAssets | 8.61M | 19.38M | 40.49M | 57.70M |
| TotalNonCurrentAssets | 4.43M | 4.83M | 4.17M | 7.49M |
| OtherNonCurrentAssets | 1.11M | 1.69M | 1.20M | 1.32M |
| InvestmentsAndAdvances | 0.00 | |||
| InvestmentinFinancialAssets | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 2.59M | 2.31M | 1.94M | 1.97M |
| OtherIntangibleAssets | 2.59M | 2.31M | 1.94M | 1.97M |
| NetPPE | 726.00K | 824.00K | 1.02M | 4.20M |
| AccumulatedDepreciation | -1.36M | -1.32M | -2.04M | -2.21M |
| GrossPPE | 2.08M | 2.15M | 3.06M | 6.40M |
| OtherProperties | 618.00K | 697.00K | 829.00K | 149.00K |
| MachineryFurnitureEquipment | 1.47M | 1.45M | 2.23M | 2.35M |
| Properties | 0.00 | 3.90M | ||
| CurrentAssets | 4.18M | 14.56M | 36.32M | 50.21M |
| OtherCurrentAssets | 199.00K | 302.00K | 455.00K | 304.00K |
| PrepaidAssets | 304.00K | |||
| Receivables | 0.00 | 1.18M | 1.68M | 1.64M |
| OtherReceivables | 1.18M | 1.68M | 1.64M | |
| AccountsReceivable | 1.68M | 1.64M | ||
| CashCashEquivalentsAndShortTermInvestments | 3.98M | 13.07M | 34.19M | 48.27M |
| OtherShortTermInvestments | 2.28M | 7.63M | 7.14M | 16.18M |
| CashAndCashEquivalents | 1.70M | 5.44M | 27.05M | 32.09M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -15.44M | -21.85M | -16.38M | -14.60M |
| RepaymentOfDebt | -251.00K | 0.00 | 0.00 | -4.85M |
| IssuanceOfDebt | 2.50M | 0.00 | ||
| IssuanceOfCapitalStock | 892.00K | 485.00K | 80.00K | 13.04M |
| CapitalExpenditure | -556.00K | -585.00K | -271.00K | -633.00K |
| EndCashPosition | 1.70M | 5.44M | 27.05M | 32.09M |
| BeginningCashPosition | 5.44M | 27.05M | 32.09M | 38.50M |
| ChangesInCash | -3.74M | -21.61M | -5.04M | -6.41M |
| FinancingCashFlow | 6.44M | 485.00K | 80.00K | 8.19M |
| CashFlowFromContinuingFinancingActivities | 6.44M | 485.00K | 80.00K | 8.19M |
| ProceedsFromStockOptionExercised | 3.30M | 0.00 | ||
| NetCommonStockIssuance | 892.00K | 485.00K | 80.00K | 13.04M |
| CommonStockIssuance | 892.00K | 485.00K | 80.00K | 13.04M |
| NetIssuancePaymentsOfDebt | 2.25M | 0.00 | 0.00 | -4.85M |
| NetLongTermDebtIssuance | 2.25M | 0.00 | 0.00 | -4.85M |
| LongTermDebtPayments | -251.00K | 0.00 | 0.00 | -4.85M |
| LongTermDebtIssuance | 2.50M | 0.00 | ||
| InvestingCashFlow | 4.71M | -832.00K | 10.99M | -631.00K |
| CashFlowFromContinuingInvestingActivities | 4.71M | -832.00K | 10.99M | -631.00K |
| NetInvestmentPurchaseAndSale | 5.26M | -294.00K | 7.36M | -243.00K |
| SaleOfInvestment | 5.62M | 1.30M | 10.08M | 22.29M |
| PurchaseOfInvestment | -361.00K | -1.59M | -2.72M | -22.54M |
| NetIntangiblesPurchaseAndSale | -538.00K | -585.00K | -185.00K | -592.00K |
| PurchaseOfIntangibles | -538.00K | -585.00K | -185.00K | -592.00K |
| NetPPEPurchaseAndSale | -18.00K | 47.00K | 3.81M | 204.00K |
| SaleOfPPE | 0.00 | 47.00K | 3.90M | 245.00K |
| PurchaseOfPPE | -18.00K | 0.00 | -86.00K | -41.00K |
| OperatingCashFlow | -14.89M | -21.27M | -16.11M | -13.96M |
| CashFlowFromContinuingOperatingActivities | -14.89M | -21.27M | -16.11M | -13.96M |
| ChangeInWorkingCapital | 296.00K | 7.13M | 966.00K | 895.00K |
| ChangeInOtherCurrentLiabilities | -309.00K | -274.00K | 688.00K | -30.00K |
| ChangeInOtherCurrentAssets | 576.00K | -486.00K | -83.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -1.26M | 7.25M | 547.00K | -189.00K |
| ChangeInAccruedExpense | -1.20M | 1.18M | 368.00K | -4.00K |
| ChangeInInterestPayable | 0.00 | |||
| ChangeInPayable | -60.00K | 6.07M | 179.00K | -185.00K |
| ChangeInAccountPayable | -60.00K | 6.07M | 179.00K | -185.00K |
| ChangeInPrepaidAssets | 103.00K | 153.00K | -151.00K | 1.63M |
| ChangeInReceivables | 1.18M | 492.00K | -35.00K | -517.00K |
| ChangesInAccountReceivables | 0.00 | 34.00K | ||
| OtherNonCashItems | 605.00K | 287.00K | -680.00K | 2.78M |
| StockBasedCompensation | 686.00K | 243.00K | 954.00K | 1.57M |
| ProvisionandWriteOffofAssets | 0.00 | |||
| AssetImpairmentCharge | 48.00K | 14.00K | 0.00 | 1.78M |
| DeferredTax | 0.00 | 197.00K | -2.32M | |
| DeferredIncomeTax | 0.00 | 197.00K | -2.32M | |
| DepreciationAmortizationDepletion | 246.00K | 238.00K | 256.00K | 775.00K |
| DepreciationAndAmortization | 246.00K | 238.00K | 256.00K | 775.00K |
| AmortizationCashFlow | 209.00K | 199.00K | 218.00K | 116.00K |
| AmortizationOfIntangibles | 209.00K | 199.00K | 218.00K | 116.00K |
| Depreciation | 37.00K | 39.00K | 38.00K | 659.00K |
| OperatingGainsLosses | 551.00K | -218.00K | 1.64M | -314.00K |
| GainLossOnInvestmentSecurities | 551.00K | -200.00K | 1.64M | -98.00K |
| GainLossOnSaleOfPPE | 0.00 | -18.00K | 0.00 | -216.00K |
| NetIncomeFromContinuingOperations | -17.32M | -28.96M | -19.45M | -19.13M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AIM
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|